Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

por Hutchinson, Susan, Dodick, David W., Treppendahl, Christina, Bennett, Nathan L., Yu, Sung Yun, Guo, Hua, Trugman, Joel M.
Publicado 2021

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

por Ailani, Jessica, Lipton, Richard B., Hutchinson, Susan, Knievel, Kerry, Lu, Kaifeng, Butler, Matthew, Yu, Sung Yun, Finnegan, Michelle, Severt, Lawrence, Trugman, Joel M.
Publicado 2020

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II

por Dodick, David W., Lipton, Richard B., Ailani, Jessica, Halker Singh, Rashmi B., Shewale, Anand R., Zhao, Sihui, Trugman, Joel M., Yu, Sung Yun, Viswanathan, Hema N.
Publicado 2020

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain

por Lipton, Richard B., Dodick, David W., Goadsby, Peter J., Burstein, Rami, Adams, Aubrey M., Lai, Jeff, Yu, Sung Yun, Finnegan, Michelle, Kuang, Amy W., Trugman, Joel M.
Publicado 2022